PMX1 is a member of a non-clustered homeobox gene family, not normally expressed in hematopoietic cells, and first identified for its role in enhancing the binding of the serum response factor (SRF) to the serum responsive element (SRE). PMX1 has never been linked to leukemia on its own, raising the possibility of unique mechanisms underlying the oncogenicity of NUP98-PMX1. To elucidate the leukemogenic potential of NUP98-PMX1, we compared the effects of PMX1 and NUP98-PMX1 and, through strategic mutations, the involvement of the SRE in NUP98-PMX1-mediated leukemia. NUP98-PMX1, but not PMX1, had potent ability to impair differentiation, promote proliferation of myeloid progenitors, induce lethal myeloproliferative disease and to activate a number of genes previously linked to leukemic stem cells. Similar to NUP98-HOX fusions, the transforming potential of NUP98-PMX1 required the NUP98 portion and DNA-binding capability of the PMX1 homeodomain and collaborated with Meis1 to induce more rapid onset myeloproliferative-like myeloid leukemia. The transforming activity of NUP98-PMX1 was independent of its ability to interact with SRF. These findings provide novel evidence of the contributory role of the NUP98 sequence in conferring leukemogenic properties on a partner gene and point to common leukemogenic pathways for NUP98-PMX1 and NUP98-clustered HOX fusions.
Introduction
The nucleoporin gene NUP98 on chromosome 11p15 is involved in chromosomal rearrangements with at least 20 different partners (Slape and Aplan, 2004; Nakamura, 2005; Romana et al., 2006; Jankovic et al., 2008) . NUP98 translocations have been described in de novo acute and chronic leukemias, as well as therapyrelated myelodysplastic syndrome and therapy-related acute myeloid leukemia (AML). Although these NUP98-associated diseases are relatively rare, they are recurring and are characterized by their aggressiveness and disappointing treatment outcome.
NUP98 is a component of the nuclear pore complex that regulates the transport of proteins and RNAprotein complexes between the cytoplasm and nucleus (Griffis et al., 2002 (Griffis et al., , 2003 . It belongs to a subgroup of nuclear pore proteins characterized by phenylalanineglycine repeats (FG repeats), which are interaction sites for karyopherins (importins, exportins) that serve to guide transport through the nuclear pore complex (Radu et al., 1995) . The role of nucleoporins in the malignant transformation of hematopoietic cells is only partly understood. The importance of the FG repeats in the etiology of disease is underscored by their preservation in all the fusion proteins (Slape and Aplan, 2004) . Moreover, the FG repeats are also conserved in the t(6;9)(p23;q34) chromosome translocation involving NUP214 (or CAN), which is found in patients with AML (von Lindern et al., 1992) . In the context of the translocations of NUP98 with HOXA9 and PMX1, the FG repeats of NUP98 have been shown to confer strong transcriptional activity to the chimeric proteins (Kasper et al., 1999; Bai et al., 2006) . Moreover, it has been demonstrated that the NUP98 FG repeats of NUP98-PMX1, NUP98-HOXA9 and NUP98-HOXC11 act as a docking site for both a transcriptional co-activator and correpressor (Bai et al., 2006) .
The most frequently observed NUP98 fusion partners belong to the homeobox gene family, including mostly clustered HOX genes and two non-clustered HOX genes, paired related homeobox 1 and 2 (PMX1 and PMX2) (Slape and Aplan, 2004; Romana et al., 2006) . The involvement of these latter two genes in leukemia is intriguing, as in contrast to clustered Hox genes, neither gene has been previously implicated in normal hematopoiesis or leukemogenesis. PMX1 knockout mice show limb and vertebral skeletal defects, but can survive soon after birth, suggestive of a normal hematopoietic system (Martin et al., 1995; ten Berge et al., 1998) . Moreover, PMX1 expression is not detected in hematopoietic cells (Kern et al., 1994) .
The rare t(1;11)(q23;p15) chromosome translocation, juxtaposing PMX1 and NUP98, has been identified in therapy-related AML patients (ten Berge et al., 1998; Nakamura et al., 1999; Zhang et al., 2007) . Whether the leukemogenic activity of NUP98-PMX1 is due to the aberrant expression of PMX1 in hematopoietic precursors driven by the NUP98 ubiquitous promoter, and/or whether there is a contribution of the NUP98 moiety to the leukemogenic potential of the fusion protein remains unknown.
PMX1 has a unique homeodomain (HD), which is highly similar to the Drosophila Paired domain (Cserjesi et al., 1992; Grueneberg et al., 1992) . Over the 60 amino acids comprising the HD, the PMX1 HD is 70% identical to the Paired domain and 50% to the clustered HOX HD, raising the possibility of unique mechanisms underlying its leukemogenic role. This is supported by the fact that the PMX1 HD, but not the clustered HOX HD, can impart transcriptional activity to the serum responsive element (SRE) through interaction with the serum responsive factor (SRF), which regulates a variety of genes including the oncogenes c-fos, fosB and junB (Grueneberg et al., 1992) . Moreover, SRF is known to be activated by oncogenic viral products, such as HCV core protein, HBV pX protein (Kato et al., 2000) and HTLV1 tax protein (Alexandre and Verrier, 1991) . This raises the interesting possibility that the leukemogenic process induced by NUP98-PMX1 is linked to the ability of PMX1 to mediate SRF activity. This notion has gained further support from the studies indicating that NUP98-PMX1 can exert a dominant negative effect on SRF-induced activation of c-fos expression in COS-7 and HeLa cell lines (Bai et al., 2006) . However, the relevance of these findings, obtained in non-hematopoietic experimental models, remains unclear.
In this study, we sought to shed light on the mechanisms underlying the leukemogenic potential of NUP98-PMX1. For that purpose, we exploited the murine hematopoietic model and explored and compared the effects of PMX1 and NUP98-PMX1 in hematopoiesis; we studied the involvement of the SRE in NUP98-PMX1-mediated leukemia, and explored the molecular pathways used by NUP98-PMX1 in the induction of leukemia.
Results

NUP98-PMX1
but not PMX1 has the ability to impair differentiation and promote proliferation of hematopoietic progenitor cells in vitro To begin to unravel the role of PMX1 and NUP98-PMX1 in hematopoietic cell growth and differentiation, we exploited a series of in vitro hematopoietic assays. For that purpose, PMX1 or NUP98-PMX1 was overexpressed in primary murine bone marrow (BM) cells (see Figures 1a and b for description of the cDNAs and vectors used). Proviral integrity was verified by Southern blot analysis (data not shown) and the expression of PMX1 and NUP98-PMX1 was confirmed by western blot analysis (Figure 1c ).
Immediately following retroviral infection and without any selection for transduced cells, BM cells were plated in liquid culture containing interleukin-3, -6 and stem cell factor. The GFP þ population of NUP98-PMX1-transduced BM cells gradually increased from the input level of B15% to greater than 70% after 17 days of culture (Figure 2a, left panel) . The growth advantage of NUP98-PMX1-transduced BM cells was more evident when comparing the in vitro growth rates of the GFP þ cell populations. NUP98-PMX1-transduced BM cells showed a B40-fold increase in total cell number over 17 days compared with GFP þ control BM cells (Figure 2a, right panel) . In contrast to this, in the PMX1-transduced BM cells, the GFP þ population was decreased from 29% of input level to less than 10% after 17 days of culture (Figure 2a These differential growth-promoting effects were further evident in colony-forming unit-spleen (CFU-S) assays, which detect primitive hematopoietic progenitor cells capable of forming spleen colonies. BM cells transduced with GFP þ control, PMX1 or NUP98-PMX1 were isolated by fluorescence-activated cell sorting (FACS) 2 days post-transduction and transplanted into lethally irradiated recipient mice. The progenitor cell frequency was equivalent among the different experimental arms, whereas NUP98-PMX1-transduced BM cells produced much larger spleen colonies (data not shown). More strikingly, after 7 days of liquid culture, NUP98-PMX1-transduced BM cells increased the absolute yield of CFU-S 100-fold compared with numbers before culture, or 5000-fold when compared with the number of CFU-S recovered from GFP þ -transduced control cultures (Figure 2b ). Conversely, PMX1-transduced BM cells had no impact on the CFU-S numbers after 1 week of liquid culture compared with GFP þ control ( Figure 2b ). FACS analysis of spleen colonies derived from NUP98-PMX1 BM cells indicated a marked increase in the proportion of granulocytic (Gr-1) myeloid cells (74.3 ± 0.7 versus 24.9 ± 3.4% for GFP þ control) and a significant decrease in the proportion of TER119 þ erythroid cells (16.2±1.2 versus 69.0±3.8% in GFP þ control). C-kit expression was also retained in a high proportion of NUP98-PMX1-transduced BM cells in spleen colonies (58.9±3.3 versus 9.4±3.2% in GFP þ control). These findings suggest that NUP98-PMX1, but not PMX1, impairs BM differentiation.
The effect of NUP98-PMX1 on hematopoietic differentiation was further evaluated after 3 weeks in liquid culture by morphology and immunophenotyping. Wright-Geisma stained cytospin preparations and FACS analysis of GFP þ control and PMX1-transduced BM cells showed highly granulated mast cell-like morphology (data not shown) and high-level expression of c-Kit and FceR (Figure 2c ), consistent with terminal differentiation. Under the same condition, the NUP98-PMX1-transduced BM cells showed immature myeloidlike morphology (data not shown) and phenotype (negative expression of FceR and low levels of c-Kit) ( Figure 2c ).
The ability of NUP98-PMX1, but not PMX1, to promote the proliferation of hematopoietic progenitors was further confirmed by serial replating of BM 
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K Hirose et al clonogenic progenitor cells in methylcellulose culture. NUP98-PMX1 strongly increased the number of secondary myeloid colony-forming cells in methylcellulose culture ( Figure 2d ). Furthermore, most of the colonies were CFU-granulocyte macrophage (Gr-1, Mac1) with high-proliferative potential (made up of several thousand cells after 8-10 days culture) and could be serially replated over three passages. In contrast, PMX1-transduced BM cells behaved as the GFP þ control, forming only mast cell colonies that lost their replating potential after the secondary plates (Figure 2d ). Figure 3a ). In contrast, the fraction of GFP þ WBC in PMX1 mice was decreased by 10-fold (to 3 ± 3.3%) compared with their proportion at the time of transplant (30±5.3%) (Figure 3a) . Moreover, the donor cells transduced with NUP98-PMX1 preferentially yielded myeloid progeny, as shown by a fourfold increase in the percentage of Gr-1/Mac1 positive cells and two-to fourfold decrease in the percentage of the lymphoid markers CD4/CD8 in the GFP þ compartment (Figure 3b ). PMX1-transduced cells retained normal multilineage differentiation ability, with proportions of B220, Gr-1/Mac1 and CD4/CD8 positive cells similar to GFP þ control mice (Figure 3b ). These observations were further supported by an increase in the absolute numbers of circulating myeloid cells in NUP98-PMX1 mice compared with those in GFP þ control or PMX1 mice (Figure 3c ).
NUP98-PMX1 but not
NUP98-PMX1 but not PMX1 causes a lethal myeloproliferative disease
Consistent with the ability of NUP98-PMX1 to confer an in vivo growth advantage and to promote myelopoiesis, a large proportion (8 out of 16) of NUP98-PMX1 mice succumbed to a myeloproliferative disorder between 170 and 300 days post-transplantation (mean disease latency of these mice is 246 days) (Figure 4a ). Although a small number of GFP þ control and PMX1 mice also died in this follow-up period, no hematological abnormalities were detected in these animals. At the time of killing, NUP98-PMX1 mice displayed severe anemia, leukocytosis and splenomegaly (Supplementary Table 1 ). Morphological analysis of PB and BM smears showed predominance of band forms and generally low percentage of metamyelocytes (Figure 4b ). Cytospin preparations (data not shown) and FACS analysis (Figure 4c ) of splenocytes revealed significant infiltration by cells with myeloid characteristics. FACS analysis of PB, BM and spleen revealed that the majority of the cells were NUP98-PMX1-transduced cells (GFP þ cells). The myeloid nature of the disease was confirmed by the finding that most of the GFP þ cells expressed Mac1/ Gr-1 but not the lymphoid markers B220, CD4 or CD8 (Figure 4c ). The accumulation of myeloid cells in BM, PB and spleen confirmed the diagnosis of myeloproliferative disease. Proviral integrity and clonality of the disease was assessed by Southern blot analysis, which revealed a mono-or pauci-clonal disease (data not shown). Hematological disease in animals transplanted with GFP þ control or PMX1 BM cells over 12 months (all the hematological parameters tested were within normal range, data not shown) was not detected, further confirming the inability of PMX1 to perturb hematopoiesis.
Taken together, the results presented above demonstrate the ability of NUP98-PMX1 to cause myeloproliferative disease consistent with perturbed differentiation and growth promotion of myeloid progenitors. Ectopic expression of PMX1 in BM cells did not perturb hematopoiesis, in contrast to the reported leukemogenic effects of the native clustered HOX partners of NUP98.
The transforming potential of NUP98-PMX1 requires the NUP98 portion and the DNA binding activity of the PMX1 HD but not the interaction of the PMX1 sequence with the SRF Our data indicating that PMX1 lacks leukemogenic activity suggests a critical role for the NUP98 portion in the activity of the fusion protein. The NUP98 sequence alone does not confer growth advantage in liquid culture (Gurevich et al., 2004) , nor does it promote in vitro transformation (Kasper et al., 1999) , strongly suggesting an essential contribution of the PMX1 portion. Thus, in an attempt to functionally dissect the contributing domains of the fusion protein to its leukemogenic potential, a series of NUP98-PMX1 mutants were tested in vitro.
To examine if the transforming ability of NUP98-PMX1 is dependent on the SRF pathway, we generated a NUP98-PMX1 mutant which has two amino-acid substitutions in the second helix of the PMX1 HD, thus removing its ability to interact with the SRF (NUP98-PMX1(ED)) (Simon et al., 1997) . The NUP98-PMX1(ED) mutant conferred a competitive growth advantage equivalent to wild-type NUP98-PMX1. Indeed, the total cell numbers of NUP98-PMX1(ED)-transduced BM cells was 17-to 20-fold greater than GFP þ control cells after 3 weeks of culture, effects comparable to wild-type NUP98-PMX1 (Figure 5a ). In CFU-S assays, NUP98-PMX1(ED) expanded the spleen colony-forming progenitor cells after 7 days in liquid culture to levels similar to the wild-type NUP98-PMX1 (data not shown). This was further confirmed in methylcellulose cultures, in which NUP98-PMX1(ED) behaved similarly to wild-type NUP98-PMX1, forming large CFU-GM colonies that could be serially replated at least three times (Figure 5b ).
To confirm that the NUP98 portion plays a critical role in leukemogenesis, we made a deletion mutant of NUP98-PMX1, which lacks the entire portion of NUP98 (PMX1 exon 2). Furthermore, to assess the importance of DNA binding of PMX1 in the leukemogenic potential of NUP98-PMX1, the highly conserved asparagine residue at position 51 in the HD of PMX1 was substituted for glutamine (NUP98-PMX1 (N51Q)). This mutation eliminates the DNA-binding activity of the HD without affecting its binding to SRF (Grueneberg et al., 1992; Vershon et al., 1995) . In contrast to NUP98-PMX1 and NUP98-PMX1(ED), PMX1 exon 2-and NUP98-PMX1(N51Q)-transduced BM cells had no competitive growth advantage in liquid culture and generated equal numbers of CFU-S compared with GFP þ control BM cells (Figure 5a and data not shown, respectively). Moreover, in methylcellulose progenitor assays, PMX1 exon 2-and NUP98-PMX1(N51Q)-transduced BM cells rapidly lost their replating potential (Figure 5b ) and produced only mast cell colonies on secondary replating (data not shown).
Collectively, these results demonstrate that the transforming activity of NUP98-PMX1 is independent of the SRF pathway, requires the NUP98 portion and must retain the DNA-binding ability of PMX1, emphasizing the similarity between NUP98-PMX1 and NUP98-HOX fusions.
Both NUP98-PMX1 and clustered NUP98-HOX collaborate with Meis1 to induce leukemia The similarities between the effects of NUP98-PMX1 and NUP98-HOX in hematopoietic development and the essential role of their HDs indicate a strong Leukemogenic properties of NUP98-PMX1 K Hirose et al redundancy in the mechanisms underlying their leukemogenic potential. To further analyse this issue, we sought to determine whether NUP98-PMX1 could collaborate with Meis1. We and others have previously shown that Meis1 is a potent collaborator of NUP98-clustered HOX fusions in the induction of AML Thorsteinsdottir et al., 2001; Pineault et al., 2003 Pineault et al., , 2004 . BM cells co-transduced with NUP98-PMX1 and Meis1 were transplanted into lethally irradiated mice (NUP98-PMX1/Meis1). FACS analysis of transduced BM cells at the time of transplantation revealed that the proportion of Meis1, NUP98-PMX1 and doubly transduced BM cells was 10.7, 6.7 and 1.9%, respectively. Each recipient mouse was transplanted with 1 Â 10 6 unsorted BM cells. When analysed at 106 days post-transplantation, doubly transduced PB cells were detectable in all recipients in proportions ranging from 17 to 50% (data not shown), a significant expansion from input levels. The increase in the myeloid compartment of these mice Leukemogenic properties of NUP98-PMX1 K Hirose et al was donor-derived and was similar to that seen in NUP98-PMX1 mice (data not shown). The leukemic collaboration between NUP98-PMX1 and Meis1 was supported by the development of myeloid leukemia in the NUP98-PMX1/Meis1 mice with a median disease latency of 191 days (Figure 6a ). These mice presented with massive ascites and splenomegaly. The myeloid nature of the disease was confirmed by FACS analysis (Figure 6b ). Morphological analysis of cytospin preparations revealed an accumulation of myeloblasts in BM (ranging from 11 to 19%, n ¼ 4) and PB (Figure 6c ), consistent with a diagnosis of myeloproliferative-like myeloid leukemia (Kogan et al., 2002) . Histological analysis of these mice revealed that leukemic cells infiltrated the spleen, liver and kidney and destroyed their normal architecture (data not shown). The disease was transplantable where all secondary recipients transplanted with doses of 1 Â 10 6 and 0.1 Â 10 6 BM cells succumbed to disease 40 days post-transplantation (Figure 6a ).
Differential transcriptional properties of PMX1 and NUP98-PMX1
Gene expression profiling on primary AML samples and studies on mixed lineage leukemia oncogenic fusion genes have revealed that a common characteristic of AML is dysregulated expression of select HOX genes and that this may be critical for leukemic stem cell (LSC) function (extensively reviewed by (Eklund, 2006 (Eklund, , 2007 Argiropoulos and Humphries, 2007) ). To gain insight into the molecular mechanisms underlying the leukemogenicity of NUP98-PMX1, we quantitatively assessed Hoxa cluster gene expression in mouse stem cell virus-yellow fluorescent protein (MIY) empty vector control, PMX1, NUP98-PMX1 and NUP98-PMX1-N51Q-transduced lineage depleted, Sca1 þ (Lin-Sca þ ) BM cells. Similar to NUP98-HOXD13 (Palmqvist et al., 2007) , NUP98-NSD1 (Wang et al., 2007) and NUP98-HHEX (Jankovic et al., 2008) , NUP98-PMX1 strongly activated multiple Hoxa cluster genes, including Hoxa5 to Hoxa10, compared with MIY control and the non-leukemogenic PMX1 and NUP98-PMX1(N51Q) (Figure 7a, left panel) . Furthermore, only NUP98-PMX1 activated expression of Bmi1, Flt3 and Cd34 (Figure 7a, right panel) , genes associated with hematopoietic and LSCs (Wang et al., 2006; Argiropoulos and Humphries, 2007) .
To further study the similarities between NUP98-clustered HOX and NUP98-PMX1, we investigated their ability to activate common target genes. We have previously shown that overexpression of NUP98-HOXD13 leads to increased levels of Hoxa9 mRNA (Pineault et al., 2003; Palmqvist et al., 2007) . Thus, we first determined whether this effect is mediated by the ability of NUP98-HOXD13 to activate the Hoxa9 promoter and whether this can be mimicked by NUP98-PMX1. As shown in Figure 7b (left panel), luciferase assays performed in 293 T cells demonstrated that both NUP98-PMX1 and NUP98-HOXD13 activated the Hoxa9 promoter linked to a luciferase reporter gene. Interestingly, PMX1 was inactive suggesting that 
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K Hirose et al fusion to NUP98 alters its transactivation properties or target specificity. In contrast, expression of an SREluciferase reporter construct was enhanced by both PMX1 and NUP98-PMX1, but not by NUP98-HOXD13, providing further evidence of dissociation of the leukemogenic activity of these NUP98-fusions and the ability to activate expression through the SRF pathway.
To test whether the differences in Hoxa9 transcriptional activation reflect differential binding capacities of PMX1 or NUP98-PMX1 to Hoxa9, chromatin immunoprecipitation experiments were conducted on highly Figure 6 NUP98-PMX1 cooperates with Meis1 to induce fatal myeloproliferative-like myeloid leukemia. (a) Survival curves for mice transplanted with bone marrow (BM) cells transduced with Meis1 alone (n ¼ 5), or MEIS1 þ NUP98-PMX1 (n ¼ 10). MEIS1 þ NUP98-PMX1 mice developed disease significantly earlier when compared to NUP98-PMX1 mice (see Figure 4a) , as determined by a log-rank test (Po0.0005). (b) Fluorescence-activated cell sorting phenotype for BM and peripheral blood (PB) cells of a control and diseased NUP98-PMX1/Meis1 mouse. (c) Wright-Geimsa stained smear of a cytospin preparation of BM and PB of a leukemic NUP98-PMX1 mouse showing an accumulation of myeloblasts (arrows).
Leukemogenic properties of NUP98-PMX1 K Hirose et al purified Lin-Sca þ BM cells transduced with PMX1, NUP98-PMX1 and NUP98-PMX1(N51Q). As shown in Figure 7c , PMX1 and NUP98-PMX1 associate with a specific Hoxa9 regulatory sequence (R1) with similar fold enrichments over their respective controls. The DNA-binding impaired NUP98-PMX1(N51Q) failed to immunoprecipitate the R1 fragment, indicating that PMX1 and NUP98-PMX1 directly bind to the R1 region of the Hoxa9 promoter by the HD. These results provide strong evidence that Hoxa9 is a direct target of both PMX1 and NUP98-PMX1 and that fusion to NUP98 imparts transactivating functions to PMX1.
Discussion
In this study we demonstrate: (1) that NUP98-PMX1 but not native PMX1 has leukemogenic potential; (2) that the NUP98 portion and the PMX1-HD DNA binding domain but not the SRE binding sequences are important for NUP98-PMX1-induced leukemogenesis; (3) that NUP98-PMX1 and NUP98-clustered HOX fusion genes share leukemogenic pathways; (4) that NUP98-PMX1 but not PMX1 activates a number of genes associated with an LSC signature and (5) that PMX1 and NUP98-PMX1 bind to Hoxa9 regulatory sequences but only NUP98-PMX1 activates robust transcription, illustrating the transactivating properties of NUP98.
NUP98 translocations involving Paired mesoderm homeobox genes describe a unique class of homeobox gene-associated leukemias, linking human leukemia to the de novo expression of non-clustered HOX genes normally not involved in hematopoiesis. Indeed, PMX1 is normally expressed in a mesodermally restricted pattern in embryos and most abundantly in cardiac, skeletal and smooth muscle tissues in adults. However, we show here that overexpression of NUP98-PMX1 in BM cells has a potent effect in the differentiation and survival of primitive hematopoietic cells, leading to the induction of a myeloproliferative disease in mice. These results are in striking contrast to the effect of overexpression of PMX1, which resulted in a rapid reduction of the proportion of PMX1-transduced WBCs in vitro and in vivo, suggesting that it decreases the long-term engraftment ability of hematopoietic stem cells and/or restricts their proliferation.
Many of the in vitro and in vivo effects induced by NUP98-PMX1 are similar to those observed following overexpression of NUP98-clustered HOX genes. Common characteristics include the growth advantage of transduced BM cells in vitro, as well as the induction of a lethal myeloproliferative disease in transplanted mice and the ability to collaborate with Meis1 in the induction of myeloid leukemia. The possibility that different NUP98 fusions share common leukemogenic pathways is supported by our findings that NUP98-PMX1 and NUP98-HOXD13 activate Hoxa9 transcription. While the leukemogenic effects of NUP98-PMX1 in the murine BM transplantation model appear to be weaker and delayed compared with other reported NUP98-HOX fusions Thorsteinsdottir et al., 2001; Pineault et al., 2003 Pineault et al., , 2004 , these discrepancies could reflect activation of non-overlapping genetic pathways, susceptibility to additional collaborating events and/or differences in experimental methodology. The latter includes variations in retroviral gene transfer and the number of BM cells transplanted, both of which dictate the frequency of the LSC transplanted and thus the potency of the oncogene.
The non-leukemogenic nature of PMX1, which differs from the strong leukemogenic potential of the native clustered Hox partners of NUP98 (Pineault et al., 2004) , clearly underscores the potential of NUP98 to confer oncogenic activity to an otherwise non-leukemogenic partner. However, the activity of NUP98-PMX1 is clearly dependent on the PMX1 portion. Our structurefunction analysis revealed that PMX1-mediated transcriptional activation through the SRF pathway is dispensable, but its DNA binding ability was critical for transformation and activation of Hoxa9. The importance of the PMX1 HD supports previous studies suggesting that the HD is the most significant contribution of the HOX partner in NUP98 translocations involving clustered Hox genes Pineault et al., 2003) . Our results strongly argue that the linkage of PMX1 to SRF mediated pathways (Bai et al., 2006) may not be relevant to the leukemogenic activity of NUP98-PMX1.
Several non-exclusive mechanisms could explain the contribution of the NUP98 and the PMX1 sequences to NUP98-PMX1-induced leukemogenesis. First, different studies suggest that NUP98-PMX1 could function as an aberrant transcription factor that regulates expression of downstream target genes critical for transformation. Indeed, Bai et al. (2006) have shown that the NUP98 FG repeats of NUP98-PMX1 may act as a docking site for both transcriptional co-activators and correpressors, and thus confer aberrant transcription activity to the 
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K Hirose et al fused partner. In this respect, it has been shown that NUP98-HOXA9, NUP98-PMX1 and NUP98-NSD1 have increased transcriptional activity on specific promoters when compared with their respective native proteins (Kasper et al., 1999; Nakamura et al., 1999; Ghannam et al., 2004; Wang et al., 2007) . Moreover, the transcriptional repressor HHEX is converted to a transcriptional activator when fused to NUP98
Leukemogenic properties of NUP98-PMX1 K Hirose et al (Jankovic et al., 2008) . Such effects are consistent with our observation that NUP98-PMX1 but not PMX1 could enhance expression of Hoxa cluster genes. It is also possible that NUP98 changes the target specificity of the native protein, as previously shown for NUP98-HOXA9 (Ghannam et al., 2004) ; however, this is not evident in the instance of the target gene Hoxa9, as both PMX1 and NUP98-PMX1 associate with the same sequences. To date, only a few genes have been reported to be direct targets of PMX1, such as tenascin-C (McKean et al., 2003) , c-FOS (Grueneberg et al., 1992; Martin et al., 1997) and sonic hedgehog (Shh) (ten Berge et al., 2001) ; however, it is unlikely that c-FOS or Shh plays a role in NUP98-PMX1-induced leukemia, as their mRNA levels are not significantly changed in NUP98-PMX1 versus PMX1-transduced Lin-Sca þ BM (data not shown). We now provide evidence that Hoxa9 is a direct target of both PMX1 and NUP98-PMX1 and that deregulation of Hoxa9 by NUP98-PMX1 may contribute to its leukemogenic activity. In addition to aberrant transcriptional activity, other contributions of NUP98 to NUP98-PMX1-induced leukemogenic transformation could not be excluded. For example, FG repeats are known to mediate interactions with nuclear-cytoplasmic transport receptors (Radu et al., 1995) and thus it may be possible that expression of the NUP98 fusion affects the nuclear transport machinery leading to transformation. This possibility is supported by the selective changes in nuclear pore complex stoichiometry and function seen after disruption of NUP98 expression in mice (Wu et al., 2001) . Furthermore, a fusion protein involving the FGrich nucleoporin NUP214 interacts with hCM1, one of the nuclear export factors, causing its aberrant intracellular localization and the disorganization of nuclear transport, which might contribute to its oncogenic potential (Saito et al., 2004) . More recently, a deletion mutant of NUP98-HHEX lacking the 5 proximal FG repeats and the GLEBS domain of NUP98 exhibited nuclear localization differences compared with wild-type NUP98-HEXX (Jankovic et al., 2008) . Moreover, a potential novel mechanism is suggested by the finding that the GLEBS motif of NUP98 (retained in all the NUP98 fusions) binds to the mRNA export factor Rae1 to regulate chromosome segregation. Indeed, cells from mice that expressed small amounts of both Rae1 and Nup98 have severe chromosomal instability, due to the premature degradation of the mitotic regulator securing (Jeganathan et al., 2005) . As the translocation of NUP98 with PMX1 (or any other HOX partner) produces a nuclear fusion protein that has the potential to sequester Rae1 in the nucleus and reduce the amount of NUP98 present at the nucleopore, it is tempting to speculate that the leukemogenic potential of NUP98-HOX fusions could be, in part, mediated by defects in mitosis. The relevance of this potential mechanism in our model needs to be investigated.
In conclusion, we have demonstrated, for the first time, the leukemogenic potential of the paired-HOX gene PMX1 when fused to NUP98. Our results support a critical role for the NUP98 moiety present in the translocation, as well as the DNA-binding capacity of PMX1. Moreover, the discovery of common leukemogenic pathways for NUP98-PMX1 and NUP98-clustered HOX fusions provides a framework for the search for common target genes for potential therapeutic manipulation.
Materials and methods
Procedural details of cDNA constructs, retroviral vectors, Southern and Western blot analyses, cell cultivation, retroviral infection, BM transplantation, in vitro hematopoietic assays, spleen colony-forming cell assay, gene expression analysis, transient tranfections, luciferase and chromatin immunoprecipitation assays are provided in Supplementary methods.
